


Gyre Therapeutics, Inc. (GYRE)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001124105

Gyre Therapeutics, Inc. GYRE; healthcare	
Grade	A A B C D E strongest fifth of 371 graded peers percentile 8.1; sampling error 2.5 points; lower is stronger
Rank	31 of 371
Profitability	C percentile 51.0
Solvency	B percentile 27.5
Growth and financing	A/B percentile 21.5
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$166.1M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Mar 13, 2026 210 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026
Last close	\$6.76 2026-10-08; market equity \$753.8M
Price used in grade	None



A, the bull
 strongest fifth of its sector;
 letters are fifths of the 371
 graded peers

Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it


Rescans on file: B from Mar 21, 2025, A from Mar 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 13, 2026

In this section, unless otherwise specified, references to "we," "our," "us" and "our company" refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) ("Gyre Pharmaceuticals"). We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. We operate through our majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through our U.S. operations headquartered in San Diego, California.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 51.0						
Gross profitability		66.9%	32.2%	12.7	372	2025-12-31
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		6.1%	(6.6%)	89.3	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 3
Solvency, sleeve percentile 27.5						
Twelve-month failure probability		0.05%	0.07%	36.0	248	2026-06-30
Altman Z double-prime		7.11	(0.31)	13.6	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2015-12-31; latest annual assets end 2025-12-31
Current ratio		5.60x	2.96x	32.7	839	2025-12-31
Growth and financing, sleeve percentile 21.5						
Revenue growth, three-year compound		not computable	10.0%			four consecutive annual observations are required
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 12
Reinvestment rate		477.3%	37.1%	5.8	104	2025-12-31
Asset growth, three years		25.2%	2.1%	17.9	704	2025-12-31
Net share issuance, one year		3.6%	2.5%	40.8	634	2026-03-02


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 1,544,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
26	AtriCure, Inc. (ATRC)	6.8	A	
27	Intuitive Surgical Inc. (ISRG)	7.0	A	
28	iRhythm Holdings, Inc. (IRTC)	7.3	A	fortress
				balance sheet
29	Globus Medical Inc. (GMED)	7.6	A	
30	Hims & Hers Health, Inc. (HIMS)	7.8	A	
31	Gyre Therapeutics, Inc. (GYRE) <	8.1	A	fortress
				balance sheet
32	Veracyte, Inc. (VCYT)	8.4	A	
33	Alkermes plc. (ALKS)	8.6	A	
34	Si-Bone, Inc. (SIBN)	8.9	A	fortress
				balance sheet
35	Viridian Therapeutics, Inc.\DE (VRDN)	9.2	A	dilution,
				fortress
				balance sheet
36	Xtant Medical Holdings, Inc. (XTNT)	9.5	A	fortress
				balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(11.9%)	8.0%	37
Distance from 52-week high	(23.8%)	(31.4%)	61
EBIT to enterprise value	1.6%	(1.5%)	60
Free cash flow yield	(0.02%)	(1.0%)	54
Book value to price	0.14	0.28	34
Sales to price	0.15	0.31	35
Composite equity issuance, five years	216.2%	20.3%	91
Relative strength against the sector, log excess return	(0.34)	(0.14)	37

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	

Cash and equivalents	\$43.3M
Operating cash flow, four quarters	-\$4.9M
Months of runway	105.3
Days since last periodic filing	63 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	\$388,791

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$116.6M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$5.4M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
3	assets	us-gaap:Assets	\$166.1M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
4	operating income	us-gaap:OperatingIncomeLoss	-\$7.5M	2014-12-31	2016-03-09	10-K	0001193125-16-498295
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	\$29.1M	2014-12-31	2015-03-16	10-K	0001193125-15-093871
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$3.5M	2014-12-31	2015-03-16	10-K	0001193125-15-093871
7	total debt	us-gaap:LongTermDebt	\$0	2014-12-31	2015-03-16	10-K	0001193125-15-093871
8	book equity	us-gaap:StockholdersEquity	-\$109.4M	2014-12-31	2017-03-08	10-K	0001564590-17-003722
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$1.5M	2014-12-31	2017-03-08	10-K	0001564590-17-003722
10	total debt	us-gaap:LongTermDebt	\$1.1M	2013-12-31	2014-03-14	10-K	0001193125-14-099974
11	book equity	us-gaap:StockholdersEquity	-\$103.0M	2013-12-31	2016-03-09	10-K	0001193125-16-498295
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$2.8M	2013-12-31	2016-03-09	10-K	0001193125-16-498295
13	net income	us-gaap:NetIncomeLoss	\$9.9M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.0M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
15	assets	us-gaap:Assets	\$125.4M	2024-12-31	2026-03-13	10-K	0001193125-26-106251
16	current assets	us-gaap:AssetsCurrent	\$102.4M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
17	current liabilities	us-gaap:LiabilitiesCurrent	\$18.3M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$68.4M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
19	operating income	us-gaap:OperatingIncomeLoss	\$11.5M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
20	book equity	us-gaap:StockholdersEquity	\$106.0M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
21	liabilities	us-gaap:Liabilities	\$23.9M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$680,000	2014-12-31	2016-03-09	10-K	0001193125-16-498295
23	operating income	us-gaap:OperatingIncomeLoss	-\$13.8M	2015-12-31	2017-03-08	10-K	0001564590-17-003722
24	interest expense	us-gaap:InterestExpense	\$1.5M	2015-12-31	2017-03-08	10-K	0001564590-17-003722
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$105.8M	2024-12-31	2026-03-13	10-K	0001193125-26-106251
26	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$113.5M	2023-12-31	2025-03-17	10-K	0000950170-25-040279
27	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$7.3M	2021-12-31	2022-03-31	10-K	0001564590-22-012877
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.2M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
29	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$2.5M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
30	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItemsAndLossFromEquityMethodInvestments	\$14.4M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
31	income tax	us-gaap:IncomeTaxExpenseBenefit	\$4.6M	2025-12-31	2026-03-13	10-K	0001193125-26-106251
32	current assets	us-gaap:AssetsCurrent	\$64.8M	2024-12-31	2026-03-13	10-K	0001193125-26-106251
33	current liabilities	us-gaap:LiabilitiesCurrent	\$19.5M	2024-12-31	2026-03-13	10-K	0001193125-26-106251
34	assets	us-gaap:Assets	\$116.5M	2023-12-31	2025-03-17	10-K	0000950170-25-040279
35	assets	us-gaap:Assets	\$84.8M	2022-12-31	2024-03-27	10-K	0000950170-24-037242
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	96,963,611	2026-03-02	2026-03-13	10-K	0001193125-26-106251
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	93,612,442	2025-03-07	2025-03-17	10-K	0000950170-25-040279